These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17125835)

  • 1. Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide.
    Zou YS; Fink SR; Stockero KJ; Paternoster SF; Smoley SA; Tun HW; Reeder CB; Tefferi A; Dewald GW
    Leuk Res; 2007 Sep; 31(9):1185-9. PubMed ID: 17125835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescence in situ hybridization for del(5q) in myelodysplasia/acute myeloid leukemia: comparison of EGR1 vs. CSF1R probes and diagnostic yield over metaphase cytogenetics alone.
    Sun Y; Cook JR
    Leuk Res; 2010 Mar; 34(3):340-3. PubMed ID: 19608274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus.
    Platzbecker U; Mohr B; von Bonin M; Binder M; Schetelig J; Ehninger G; Bornhäuser M
    Leukemia; 2007 Nov; 21(11):2384-5. PubMed ID: 17581611
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.
    Kelaidi C; Park S; Brechignac S; Mannone L; Vey N; Dombret H; Aljassem L; Stamatoullas A; Adès L; Giraudier S; de Botton S; Raynaud S; Lepelley P; Picard F; Leroux G; Daniel MT; Bouscary D; Dreyfus F; Fenaux P;
    Leuk Res; 2008 Jul; 32(7):1049-53. PubMed ID: 18191202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
    Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Submicroscopic deletions in 5q- associated malignancies.
    Crescenzi B; La Starza R; Romoli S; Beacci D; Matteucci C; Barba G; Aventin A; Marynen P; Ciolli S; Nozzoli C; Martelli MF; Mecucci C
    Haematologica; 2004 Mar; 89(3):281-5. PubMed ID: 15020265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
    Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion.
    Peñarrubia MJ; Silvestre LA; Conde J; Cantalapiedra A; Garcia Frade LJ
    Leuk Res; 2009 Jun; 33(6):e8-9. PubMed ID: 19168219
    [No Abstract]   [Full Text] [Related]  

  • 10. Van-den Berghe's 5q- syndrome in 2008.
    Mohamedali A; Mufti GJ
    Br J Haematol; 2009 Jan; 144(2):157-68. PubMed ID: 19016715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series.
    Coutinho R; Costa D; Carrió A; Muñoz C; Vidal A; Belkaid M; Campo E; Nomdedeu B
    Ann Hematol; 2010 Oct; 89(10):1069-70. PubMed ID: 20232065
    [No Abstract]   [Full Text] [Related]  

  • 12. Cryptic deletion of EGR1 in association with a novel balanced t(5;22)(q31;q11.2) in a patient with myelodysplastic syndrome.
    Hoffman MW; Janney S; Batanian JR
    Cancer Genet Cytogenet; 2009 Jun; 191(2):106-8. PubMed ID: 19446747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular genetic evidence of Y chromosome loss in male patients with hematological disorders.
    Zhang LJ; Shin ES; Yu ZX; Li SB
    Chin Med J (Engl); 2007 Nov; 120(22):2002-5. PubMed ID: 18067786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.
    Eclache V; Da Rocha A; Le Roux G; Fenaux P
    Haematologica; 2008 Feb; 93(2):315-6. PubMed ID: 18245660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
    Hadiji Mseddi S; Kallel F; Kassar O; Elloumi M; Jedidi I; Sennana H; Fenaux P
    Leuk Res; 2011 Sep; 35(9):e175-6. PubMed ID: 21658768
    [No Abstract]   [Full Text] [Related]  

  • 16. [Detection of -5/5q- chromosome abnormality in myelodysplastic syndromes by interphase fluorescence in situ hybridization].
    Shen Y; Xue Y; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2001 Oct; 22(10):517-9. PubMed ID: 11769675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
    Melchert M; Kale V; List A
    Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
    Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
    Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission.
    Adès L; Eclache V; Gardin C; Boehrer S; Leroux G; Martiat P; Fenaux P
    Bone Marrow Transplant; 2010 Apr; 45(4):791-2. PubMed ID: 19718061
    [No Abstract]   [Full Text] [Related]  

  • 20. [Detection of cytogenetic abnormalities involving chromosomes 5,7 and 8 in myelodysplastic syndromes with fluorescence in situ hybridization and its clinical significance].
    Cai Y; Qin YW; Wang C; Yang J; Yan SK
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):6-10. PubMed ID: 17649717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.